Aquestive therapeutics announces completion of fda end-of-phase 2 meeting for aqst-109 (epinephrine sublingual film)

Warren, n.j., dec. 22, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (the “company” or “aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced the completion of its end-of-phase 2 (eop2) meeting with the u.s. food and drug administration (“fda”) for aqst-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.
AQST Ratings Summary
AQST Quant Ranking